ArticleIn vivo (Athens, Greece)
Long-term Efficacy and Safety of Carbon-ion Radiotherapy for Thoracic Chordoma: A Case Report.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimWe report a case of inoperable thoracic chordoma successfully treated with carbon-ion radiotherapy (C-ion RT). CASE REPORT: A 65-year-old male patient underwent computed tomography for evaluation of a benign thyroid nodule and was incidentally diagnosed with thoracic chordoma without metastasis. A physical examination revealed increased tendon reflexes in the lower extremities. Magnetic resonance imaging revealed a tumour measuring 52 mm in maximum diameter, located from the seventh cervical to the third thoracic vertebrae, compressing a wide area of the spinal cord. The patient was unsuitable for surgery due to the high risk of severe postoperative neurological dysfunction. The patient received C-ion RT at a total dose of 64.0 Gy (relative biological effectiveness), delivered in 16 fractions. The patient completed C-ion RT as scheduled; however, the patient experienced transient Lhermitte's sign, classified as grade 1 acute neuropathy, during treatment. The patient is alive 96 months after C-ion RT initiation with no evidence of local recurrence or distant metastasis, remains ambulatory, and has developed no grade 2 or higher toxicities other than the grade 1 neuropathy that was present prior to the initiation of C-ion RT.
conclusionWe observed a favourable local response with manageable toxicity in a patient with thoracic chordoma treated with C-ion RT. Although this is a single-case report, our findings suggest that C-ion RT could be considered a viable treatment option for thoracic chordomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.